<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03194126</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2016/VL-01</org_study_id>
    <nct_id>NCT03194126</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy of Two Therapeutic Strategies for Cervical Maturation Before Medical Termination</brief_title>
  <acronym>IMEGYN</acronym>
  <official_title>Evaluation of Efficacy of Two Therapeutic Strategies for Cervical Maturation Before Medical Termination: Mechanical Plus Medicinal Maturation vs Medicinal Maturation Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reducing the time patients spend in the labor and delivery room saves money and reduces
      patient discomfort as well and reducing complications. We will compare two methods for
      inducing cervical maturation in order to shorten the time taken between administration of
      drugs and delivery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 11, 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The primary outcome will be evaluated by a blinded evaluator: the laminaria placement is performed by the on-call team at Day-1, whilst the delivery is performed by a different team at Day 0, with the laminaria removed in the morning.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>time taken between administration of 1st dose of drugs and delivery between the two strategies</measure>
    <time_frame>Up to 2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare pain experienced by patients between groups</measure>
    <time_frame>Day 0 - Day 2</time_frame>
    <description>scale 0-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare cervix length before administration of misoprostol between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>in mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare degree of dilation before administration of misoprostol between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare time taken between misoprostol and delivery between groups</measure>
    <time_frame>Day 0 - Day 2</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of delivery between groups</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of delivery between groups</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of delivery between groups</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of delivery between groups</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of delivery between groups</measure>
    <time_frame>&gt;12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of endometritis between groups</measure>
    <time_frame>Day 0 - Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hemorrhage between groups</measure>
    <time_frame>Day 0 - Day 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction in peripartum between groups</measure>
    <time_frame>Day 2</time_frame>
    <description>Numeric Rating Scale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient anxiety between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>Hospital Anxiety and Depression Scale questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of any post-traumatic stress between groups</measure>
    <time_frame>3 months</time_frame>
    <description>Perinatal post-traumatic stress disorder questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Medical; Abortion, Fetus</condition>
  <arm_group>
    <arm_group_label>Misoprostol + laminaria</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mifepristone + Misoprostol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Misoprostol + 3 laminaria</intervention_name>
    <description>Three laminaria placed 12 hours prior to administration of misoprostol</description>
    <arm_group_label>Misoprostol + laminaria</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mifepristone + Misoprostol</intervention_name>
    <description>Standard maturation using 600mg mifepristone followed 36 hours later by 400mg misoprostol every 3 hours</description>
    <arm_group_label>Mifepristone + Misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be a member or beneficiary of a health insurance plan

          -  The patients is at least 18 years old

          -  Patient with a singleton pregnancy between 14 and 34 weeks gestation with an
             indication for medical termination due to maternal or fetal problem as validated by
             pluridisciplinary prenatal diagnosis center.

        Exclusion Criteria:

          -  The subject is participating in an interventional study or is in a period of exclusion
             determined by a previous study

          -  The patient is under safeguard of justice

          -  The subject refuses to sign the consent

          -  It is impossible to give the subject informed information

          -  Patient has vaginismus

          -  Patient has a cervix permitting artificial rupture of membrane

          -  Patients taking one of the following treatments, contraindicated for mifepristone:
             ketoconazole, itraconazole, erythromycin, grapefruit juice, rifampicin, dexamethasone,
             St John's wort and certain anti-convulsants (phenytoin, phenobarbital, carbamazepine).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florent Fuchs, MD</last_name>
      <phone>07 82 66 75 09</phone>
      <email>f-fuchs@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Florent Fuchs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Vintejoux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romy Rayssiguier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Therond</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Simon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Letouzey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eve Moustey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric Grosjean, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine Sarda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Ferrer</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2017</study_first_submitted>
  <study_first_submitted_qc>June 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2017</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

